Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.43 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.36 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4799254 | 1.00 | HTR2A (0.43) | HTR2AMEN1KMT2ASLC2A1CSNK1E | |
| Hydrochloric Acid SCHEMBL11785349 | 1.00 | HTR2A (0.43) | HTR2AMEN1KMT2ASLC2A1CSNK1E | |
| Hydrochloric Acid SCHEMBL6122957 | 1.00 | HTR2A (0.43) | HTR2AMEN1KMT2ASLC2A1CSNK1E | |
| Hydrochloric Acid SCHEMBL28715893 | 1.00 | HTR2A (0.43) | HTR2AMEN1KMT2ASLC2A1CSNK1E | |
| Hydrochloric Acid SCHEMBL10582696 | 1.00 | HTR2A (0.43) | HTR2AMEN1KMT2ASLC2A1CSNK1E | |
| Hydrochloric Acid SCHEMBL1170862 | 1.00 | HTR2A (0.43) | HTR2AMEN1KMT2ASLC2A1CSNK1E | |
| Hydrochloric Acid SCHEMBL4800361 | 1.00 | HTR2A (0.43) | HTR2AMEN1KMT2ASLC2A1CSNK1E | |
| Hydrochloric Acid SCHEMBL1805048 | 0.98 | HTR2A (0.42) | HTR2AMEN1KMT2ASLC2A1CSNK1E | |
| SCHEMBL9720865 | 0.98 | HTR2A (0.44) | HTR2AMEN1KMT2ASLC2A1CSNK1E | |
| SCHEMBL4801716 | 0.98 | HTR2A (0.44) | HTR2AMEN1KMT2ASLC2A1CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885326-A2 | REGULATION OF MAMMALIAN KERATINOUS TISSUE USING PERSONAL CARE COMPOSITIONS COMPRISING CETYL PYRIDINIUM CHLORIDE | The Procter and Gamble Company (US) | 2008-02-13 | — | — | EP | claimed |
| US-20070020221-A1 | Regulation of mammalian keratinous tissue using personal care compositions comprising cetyl pyridinium chloride | PROCTER & GAMBLE COMPANY, THE | 2007-01-25 | — | — | US | claimed |
| WO-2006124990-A2 | REGULATION OF MAMMALIAN KERATINOUS TISSUE USING PERSONAL CARE COMPOSITIONS COMPRISING CETYL PYRIDINIUM CHLORIDE | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-23 | — | — | WO | claimed |
| US-5008345-A | Two-Part Curing System Containing A Metallic Acid Salt And An Ammonium Or Phosphonium Quaternary Salt | ZEON CHEMICAL USA, INC. (US) | 1991-04-16 | — | — | US | claimed |
| EP-0309794-A2 | No-post-cure method of curing polyacrylate polymers | Zeon Chemicals USA, Inc. (US) | 1989-04-05 | — | — | EP | claimed |
| CN-112608781-B | Rod-shaped valve rod sealant composition and preparation method thereof | 武汉博达特种润滑技术有限公司 | 2022-07-19 | — | — | CN | disclosed |
| EP-2455365-A1 | Process for the preparation cyano carboxylic acid esters | Lonza Ltd. (CH) | 2012-05-23 | — | — | EP | disclosed |
| EP-1885326-A2 | REGULATION OF MAMMALIAN KERATINOUS TISSUE USING PERSONAL CARE COMPOSITIONS COMPRISING CETYL PYRIDINIUM CHLORIDE | The Procter and Gamble Company (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1881814-A1 | REGULATION OF MAMMALIAN KERATINOUS TISSUE USING PERSONAL CARE COMPOSITIONS COMPRISING DIETHYLHEXYL SYRINGYLIDENE MALONATE | The Procter and Gamble Company (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20070020221-A1 | Regulation of mammalian keratinous tissue using personal care compositions comprising cetyl pyridinium chloride | PROCTER & GAMBLE COMPANY, THE | 2007-01-25 | — | — | US | disclosed |
| WO-2006124990-A2 | REGULATION OF MAMMALIAN KERATINOUS TISSUE USING PERSONAL CARE COMPOSITIONS COMPRISING CETYL PYRIDINIUM CHLORIDE | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006124991-A1 | REGULATION OF MAMMALIAN KERATINOUS TISSUE USING PERSONAL CARE COMPOSITIONS COMPRISING DIETHYLHEXYL SYRINGYLIDENE MALONATE | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-0362459-B1 | Polyacrylate polymers utilizing substituted urea retarder | ZEON CHEMICALS USA INC (US) | 1994-08-10 | — | — | EP | disclosed |
| US-5292908-A | Adding alkyltrialkoxysilane | HOJUN KOGYO CO., LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| US-5081194-A | Quaternary ammonium or phosphonium curing agent | ZEON CHEMICALS U.S.A., INC. (US) | 1992-01-14 | — | — | US | disclosed |
| US-5079304-A | Curable | ZEON CHEMICALS U.S.A., INC. (US) | 1992-01-07 | — | — | US | disclosed |
| US-5008345-A | Two-Part Curing System Containing A Metallic Acid Salt And An Ammonium Or Phosphonium Quaternary Salt | ZEON CHEMICAL USA, INC. (US) | 1991-04-16 | — | — | US | disclosed |
| EP-0362459-A1 | Polyacrylate polymers utilizing substituted urea retarder | Zeon Chemicals USA, Inc. (US) | 1990-04-11 | — | — | EP | disclosed |
| EP-0309794-A2 | No-post-cure method of curing polyacrylate polymers | Zeon Chemicals USA, Inc. (US) | 1989-04-05 | — | — | EP | disclosed |
| US-3951850-A | Conversion of clay to its colloidal form by hydrodynamic attrition | CLOCKER EDWIN T | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070020221-A1 | Regulation of mammalian keratinous tissue using personal care compositions comprising cetyl pyridinium chloride | RBP1, PROC, RBP4 | HTR2A 4224/4885KCNH2 2270/4885SLC6A2 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.